Stockreport

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]

Neumora Therapeutics, Inc.  (NMRA) 
PDF Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., March 07, [Read more]